Maria Arcila, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provides an overview of liquid biopsy circulating tumor DNA (ctDNA) testing for tumor profiling and some of the potential applications in patients with non-small cell lung cancer (NSCLC). The emergence of ctDNA analysis using technologies such as next-generation sequencing (NGS) offers a non-invasive method to detect small amounts of tumor from the circulation and identify genetic alterations for diagnostic purposes, as well as during the monitoring of patients being treated with targeted therapies. This interview took place at the World Conference on Lung Cancer (WCLC) 2021.
